Late Breaking Clinical Trial Results of Investigational Anti-Cancer Drug Phenoxodiol Among Four Abstracts to be Presented at Ame
March 26 2004 - 8:58AM
PR Newswire (US)
Late Breaking Clinical Trial Results of Investigational Anti-Cancer
Drug Phenoxodiol Among Four Abstracts to be Presented at American
Association for Cancer Research Annual Meeting WASHINGTON, March 26
/PRNewswire-FirstCall/ -- Marshall Edwards, Inc. , confirmed today
that four abstracts, including two from clinical trials on its
investigational anti-cancer drug phenoxodiol, are to be presented
at the 95th Annual Meeting of the American Association for Cancer
Research (AACR) in Orlando, Florida, March 27-31, 2004, Orange
County Convention Center. The abstracts for these presentations are
available from AACR, which can be obtained using the information
below. *Late-breaking entry: Interim Results of a Phase Ib/IIa
Study of Oral Phenoxodiol in Patients with Late-Stage,
Hormone-Refractory Prostate Cancer Abstract No. LB-214
Late-Breaking Abstracts: Poster Session 2 Tuesday 3/30/04 1:00 p.m.
- 5:00 p.m. Hall B4-D Phenoxodiol phase Ib/II study in patients
with recurrent ovarian cancer that are resistant to greater than or
equal to second line chemotherapy Abstract No. 4457:
http://aacr04.agora.com/planner/displayabstract.asp?presentationid=5467
Poster Session Tuesday 3/30/2004 1:00 PM-5:00 PM Hall B4-D
Phenoxodiol a chemosensitizer in taxotere-resistant ovarian cancer
cells Abstract No. 4885:
http://aacr04.agora.com/planner/displayabstract.asp?presentationid=6039
Poster Session Wednesday 3/31/2004 8:00 AM-12:00 PM Hall B4-D
Phenoxodiol, a novel isoflavone, promotes g1/s arrest by
upregulation of p21 in head and neck squamous and salivary gland
carcinoma cell lines Abstract No. 1515:
http://aacr04.agora.com/planner/displayabstract.asp?presentationid=4950
Minisymposium Sunday3/28/2004 2:00 PM-5:30 PM Hall F1-2 Phenoxodiol
works by removing the proteins (XIAP, c-FLIP) within the cancer
cell that are responsible in large part for preventing the ability
of the cancer cell to be killed by the body and by chemotoxic
drugs. When these proteins are removed, the cancer cell is
sensitive to the body's normal defense mechanisms that are designed
to eliminate cancerous cells. This synergistic mechanism also leads
to phenoxodiol enhancing in a very potent way the sensitivity of
cancer cells to the killing ability of standard anti-cancer drugs,
as well as reversing chemo-resistance in cancer cells and restoring
their sensitivity to those standard drugs. Phenoxodiol is an
investigational drug and has not yet been approved for marketing in
the U.S. Marshall Edwards, Inc., manages its international research
and development programs using the expertise and clinical research
capabilities of universities and hospitals in the U.S., Australia
and Europe. Marshall Edwards, Inc., has licensed rights to bring
phenoxodiol to market globally from its parent company, Novogen
Limited. (NASDAQ:NVGN). Novogen is developing a range of
therapeutics across the fields of oncology, cardiovascular disease
and inflammatory diseases based on its phenolic drug technology
platform. More information on phenoxodiol and on the Novogen group
of companies can be found at http://www.marshalledwardsinc.com/ and
http://www.novogen.com/. Statements included in this press release
that are not historical in nature are "forward-looking statements"
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. You should be aware that
our actual results could differ materially from those contained in
the forward-looking statements, which are based on management's
current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and
delaysin the development and/or FDA approval, or the failure to
obtain such approval, of our product candidates; uncertainties in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaborationor
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights tothird
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of anyrevisions
to these forward-looking statements. DATASOURCE: Marshall Edwards,
Inc. CONTACT: United States: David Sheon, +1-202-518-6384, for
Marshall Edwards, Inc.; or Australia: Christopher Naughton of
Marshall Edwards, Inc., +011 61 2 9878 0088 Web site:
http://www.marshalledwardsinc.com/ http://www.novogen.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024